Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03167359 · ClinicalTrials.gov registry record · NA
Hypofractionated Radiotherapy in Breast Cancer
A NA study, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 74
- Enrollment target
NCT03167359 is a NA study that has completed, run by Emory University. The registered enrollment target is 74 participants.
The verdict
NCT03167359, a NA study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 74 participants
- Enrollment target
Study Summary
As the number of breast cancer (BrCA) survivors has markedly increased, clinicians are now seeking to reduce treatment-related toxicities and inconveniences of treatment, namely the traditional 6 weeks of daily radiation treatment (XRT). Skin thickening, fibrosis, and edema are some of the most common acute and potentially long-term debilitating toxicities of BrCA XRT. The purpose of this study is to learn if three weeks of daily radiation treatment (RT) to the breast is safe in breast cancer patients who are usually prescribed 6 weeks of daily radiation after breast surgery (e.g. lumpectomy or mastectomy) as standard of care.
Interventions
- RADIATION Hypofractionated Simultaneous Integrated Boost Radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2010-12 |
| Est. Completion | 2019-05-14 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03167359
The ClinicalTrials.gov registry entry for NCT03167359 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hypofractionated Simultaneous Integrated Boost Radiotherapy is the first listed.
NCT03167359 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03167359 about?
NCT03167359 is a clinical study titled "Hypofractionated Radiotherapy in Breast Cancer". As the number of breast cancer (BrCA) survivors has markedly increased, clinicians are now seeking to reduce treatment-related toxicities and inconveniences of treatment, namely the traditional 6 weeks of daily radiation treatment (XRT). Skin thickening, fibrosis, and edema are some of the most comm...
What is the current status of trial NCT03167359?
This trial is currently completed. It is a NA study. The enrollment target is 74 participants. The study started on 2010-12. Estimated completion is 2019-05-14.
What interventions are being tested in trial NCT03167359?
The interventions under investigation include: Hypofractionated Simultaneous Integrated Boost Radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT03167359?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.